News | September 11, 2014

Tax Savings Not Only Benefit to Medtronic-Covidien Deal

September 11, 2014 — U.S.-based Medtronic said it would purchase Ireland-based Covidien for $42.9 billion, combining two of the world's biggest medical device makers and helping Medtronic savings with a headquarters change. Kalorama estimates the deal will come just short of creating the largest device company based on 2013 revenues in its Global Market for Medical Devices, 5th Edition report, released last year. According to Kalorama, Johnson & Johnson is the largest device company at $28.5 in 2013, but if the new combined company has a strong year of sales, rankings could change.

The deal, which is being structured as a so-called inversion, will relocate Medtronic from its legal headquarters in Minneapolis to Covidien's corporate home in Ireland, where the tax rate is significantly lower than in the United States. Medtronic plans to keep significant operations in the United States. But Kalorama says the tax implications are only one aspect. A greater aspect is access to Covidien's rich distribution channels in U.S. and European hospitals.

"They are probably complementary in terms of distribution venues, and can stay out of each other's revenue lines well," said Bruce Carlson, publisher of Kalorama Information. "Covidien staples your wound, keeps track of you in the hospital while Medtronic makes your heart pump, provides a new spine, or provides your body with timed insulin. Medtronic management is not emphasizing tax savings in the press statements."

According to Kalorama's report, consolidation was a trend in the device industry. In 2013 and early 2014, key market players were active in acquiring companies, among these were Boston Scientific, Stryker Corp., CareFusion, ThermoFisher Scientfic, The Carlyle Group and Medtronic. Stryker's purchase of MAKO Surgical, Zimmer's purchase of Biomet and the sale of J&J's Ortho Clinical Diagnostic Group to the Carlyle Group were among the larger purchases.  

"The media reports are focusing on the inversion deal, but with a slow-growing device market, consolidation has been an industry trend," Carlson said. "This wouldn't be announced if there weren't real benefits to the business as well as the tax moves."

Kalorama said that together, the two companies will become one of the largest medical device makers, with 87,000 employees in more than 150 countries. Medtronic will pay $35.19 in cash and 0.956 of a share for each Covidien share. 

Kalorama's complete report on Global Market for Medical Devices, 5th Edition has a complete breakdown of 2013 and early 2014 device acquisitions.

For more information: www.kaloramainformation.com/redirect.asp?progid=86522&productid=8186981

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init